Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Up 125.8% in January

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the recipient of a large growth in short interest in January. As of January 30th, there was short interest totaling 619,061 shares, a growth of 125.8% from the January 15th total of 274,164 shares. Based on an average daily volume of 13,995,251 shares, the days-to-cover ratio is presently 0.0 days. Currently, 44.2% of the shares of the stock are sold short. Currently, 44.2% of the shares of the stock are sold short. Based on an average daily volume of 13,995,251 shares, the days-to-cover ratio is presently 0.0 days.

Shuttle Pharmaceuticals Price Performance

SHPH traded up $0.03 during trading on Thursday, hitting $1.15. 20,949 shares of the stock traded hands, compared to its average volume of 5,394,485. The firm has a market capitalization of $1.84 million, a P/E ratio of -0.10 and a beta of -1.02. Shuttle Pharmaceuticals has a 12-month low of $1.09 and a 12-month high of $17.70. The firm has a 50-day moving average of $1.79 and a 200 day moving average of $2.74.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($1.05) EPS for the quarter.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SHPH. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Shuttle Pharmaceuticals has a consensus rating of “Sell”.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

A hedge fund recently bought a new stake in Shuttle Pharmaceuticals stock. Connective Capital Management LLC bought a new stake in shares of Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 100,535 shares of the company’s stock, valued at approximately $357,000. Connective Capital Management LLC owned 9.40% of Shuttle Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 4.58% of the company’s stock.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .